WORLD NEWS
Phase 2 vitamin C trial in precancerous blood disorders did not change cell progression
EVITA assigned 109 people with precancerous blood disorders or early low-risk blood cancers to vitamin C or placebo for 12 months.
The principal biological progression measure did not improve, and the survival difference was exploratory, so it is not a reason to change supplements without clinical advice.
Trial design
Participants in Denmark and the United States were randomised: 55 received 1,000 mg/day vitamin C and 54 placebo. Treatment was double-blind for 12 months, with follow-up around three years.
What changed
The vitamin C group had fewer adverse events and shifts in some inflammatory signals. But the growth rate of abnormal cells, a marker linked to progression, did not differ significantly.
Why the survival signal is cautious
The roughly three-year survival result came from exploratory analysis. With a small sample and limited events, chance and group differences matter; a confirmatory phase 3 trial is required.
What readers should do
Vitamin C does not replace standard care, and high-dose supplements can interact with kidney disease or medicines. Discuss use with a haematology team and wait for the registered EVITA-4 phase 3 results.
Primary source and independent checks
Read in other languages
한국어 · English · Español · 日本語 · Tiếng Việt